Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Pharmacopeia gets Bristol exec

Executive Summary

Rene Belder, who led Bristol-Myers Squibb's regulatory team for the PPAR agonist Pargluva (muraglitazar), joins Pharmacopeia as VP-clinical and regulatory affairs, the Princeton, N.J. biotech announces Nov. 6. Bristol halted development of Pargluva in May, seven months after an FDA "approvable" letter for the diabetes agent suggested additional clinical trials would be necessary (1"The Pink Sheet" Dec. 19, 2005, p. 11). At Pharmacopeia, Belder will be responsible for overseeing the firm's current and future clinical development product portfolio...
Advertisement

Related Content

Bristol Swallows Cost-Cutting Pill To Dull Pargluva Pain; Sales Force May Shrink
Bristol Swallows Cost-Cutting Pill To Dull Pargluva Pain; Sales Force May Shrink
Advertisement
UsernamePublicRestriction

Register

PS047757

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel